MedMira Expands Market Presence in Latin America

MedMira Expands Market Presence in Latin America
Product Registrations Completed in Argentina, Peru and Panama 


HALIFAX, July 5  /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through
diagnostic tests, announced today that it has expanded its market presence in
Latin America with the completion of product registrations in Argentina,
Panama, and Peru. Registrations in these three key Latin American markets
enable MedMira to continue with the current tender processes leading to the
sale of its MiraWell(R) Rapid HIV Test and HIV/Hepatitis C (HCV) combination
test to healthcare facilities as well as national government sponsored
treatment and prevention programs.

MedMira along with its distributors in these regions, Genesis and Exportrade,
have been working hard to complete the rigorous medical device registration
process for its rapid flow-through diagnostic tests in these three Latin
American countries. MedMira's rapid tests are the fastest flow- through
diagnostic tests in the world, providing results in 3 minutes.

Rapid diagnostic tests present significant value in the Latin American market,
where the HIV epidemic remains concentrated among high risk groups including IV
drug users (IDU) and sex trade workers. The World Health Organization estimates
that nearly 70% of HIV-positive IDUs are also infected with HCV. People in
these high risk categories typically visit mobile testing clinics, with a very
low percentage returning for their test results. Using MedMira's tests, these
types of clinics will be able to provide immediate test results and appropriate
counselling options at the time of testing.

Giles Crouch, vice president of sales and marketing with MedMira said, "We have
established a solid foothold in other regions of Latin America, including the
Caribbean and Belize, and the time is right to expand into Argentina, Peru and
Panama. Governments in the region have realized that prevention is fundamental
in the fight against HIV/AIDS and Hepatitis C and are beginning to fund testing
and treatment programs and are demanding high- quality tests."

Crouch added, "Our strong working relationships with Exportrade and Genesis
helped us to quickly recognize the market potential in these countries and
build on their market position in the region."

According to the Regional AIDS Initiative for Latin America and the Caribbean
(SIDALAC) and the World Bank there are 2 million people living with HIV in the
region. The rate of infection is on the rise with approximately 567 people
contracting HIV every day, resulting in over 200,000 new infections per year.
Globally, as many as 40% of people who are HIV-positive may also be co-
infected with HCV. The World Health Organization estimates that there are 170
million people infected with HCV and as many as 3 to 4 million new people are
infected each year.

About MedMira

MedMira is the leading global manufacturer and marketer of in vitro flow-
through rapid diagnostic tests. MedMira's tests provide reliable, rapid
diagnosis in just 3 minutes for the detection of human antibodies in human
serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(TM) G2 and MiraWell(R) rapid HIV tests, respectively.

MedMira's Reveal(TM) G2 and MiraWell(R) rapid HIV tests are currently used in
clinical laboratories, hospitals, and clinics where professional counselling
and patient treatment are immediately available.

The MiraCare(TM) Rapid HIV Antibody Test, MedMira's over-the-counter (OTC)
product, is available in pharmacies throughout Hong Kong and Macao Special
Administrative Regions, in the People's Republic of China.

MedMira delivers rapid diagnostic solutions to healthcare communities around
the globe. Its corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada with a representative office in Beijing, China.

This news release contains forward-looking statements, which involve risk and
uncertainties and reflect the company's current expectation regarding future
events. Actual events could materially differ from those projected herein and
depend on a number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the company quarterly
filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this statement.

For more information visit MedMira's website at http://www.medmira.com/. 

DATASOURCE: MedMira Inc.



CONTACT: Dr. James Smith, Investor Relations, Tel: [phone],

E-mail: 

Copyright